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Objectives: Dapagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor 
approved for the treatment of adults with type 2 diabetes (T2DM). This study com-
pared the cost-effectiveness of dapagliflozin versus a sulfonylurea (SU) added to 
metformin in persons with T2DM inadequately controlled on metformin alone in 
Colombia. MethOds: A discrete event simulation model (Cardiff diabetes model) 
based on UKPDS 68 was used to simulate disease progression and to estimate the 
economic and health treatment consequences in people with T2DM. Epidemiologic 
and clinical efficacy parameters were obtained from the literature. The cost of medi-
cation was obtained from country level price data, SISMED and Farmaprecios; the 
cost of macro- and microvascular events was based on POS tariffs, SOAT Manual 
and consultation with a local expert. Costs were expressed in US dollars [Exchange 
rate: 1,790.6 Colombian pesos = 1$]. A 20-year time horizon was assumed. Costs and 
health outcomes were discounted at 3% annually. Deterministic and probabilistic 
sensitivity analyses (PAS) were performed. Results: The total direct cost of the 
dapagliflozin + MET group over 20 years was higher than that of the SU added to 
metformin group ($11,482,424 vs. $8,942,315). Treatment with dapagliflozin resulted 
in a greater number of quality-adjusted life years (QALYs) compared to SU com-
bination (10,861 vs. 10,439).The calculated Incremental Cost-Effectiveness Ratio 
(ICER) for dapagliflozin compared to SU was $ 6,023 per QALY gained. Using WHO’s 
criteria, dapagliflozin compared to SU treatment strategy has a 85% probability of 
being highly cost-effective (ICER< 1 GDP per capita) and 100% probability of being 
cost-effective (ICER ≤ 3 GDP per capita).The results were robust to sensitivity analy-
sis. cOnclusiOns: This study demonstrated that dapagliflozin in combination 
with metformin would be a cost-effective treatment option for patients who are 
inadequately controlled with metformin monotherapy in Colombia.
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Objectives: To evaluate the long-term cost effectiveness of once daily biphasic 
insulin aspart 30 (BIAsp 30) versus insulin glargine (IGlarg) treating people with 
type 2 diabetes mellitus (T2DM) based on social perspective in China. MethOds: 
The validated and peer-reviewed CORE Diabetes Model was employed to simulate 
disease progression and determine the total direct medical cost, life years (LYs) and 
quality-adjusted life years (QALYs) over 30 years. Simulated cohorts and treatment 
effects were based on the Chinese subgroup (n= 422) in the EasyMix study (identifier 
in ClinicalTrials.gov: NCT01123980) which was an open-label, randomized, two-arm 
and multicentre trial among insulin-naïve people with T2DM. Treatment costs were 
based on insulin doses in the trial and market retail prices in China. Management 
and complication costs were obtained from Chinese published data in 2011 and 
adjusted to the price level of 2012 with consumer price index. An annual discount-
ing rate of 3% was used for both costs and health outcomes. One-way sensitivity 
analyses were performed. Results: Treatment with BIAsp 30 was associated with 
LY gain of 0.09 (13.66 vs. 13.57) and QALY gain of 0.08 (9.72 vs. 9.64) compared with 
IGlarg over 30 years. In terms of total average cost per patient, BIAsp 30 was less 
costly than IGlarg (CNY -46,441, CNY 265,166 vs. 311,607) which was mainly induced 
by lower treatment and management cost (CNY-43,037, CNY 160,863 vs. 203,900) 
and complication cost (CNY -3404, CNY 104,303 vs. 107,707). Sensitivity analyses 
demonstrated robustness of the results. cOnclusiOns: For people with T2DM 
insufficiently controlled on OADs in China, treatment with once daily BIAsp 30 
was projected to be associated with improved life expectancy and reduced direct 
medical cost compared to IGlarg. BIAsp 30 represented a dominant treatment option 
compared to IGlarg for people with T2DM failing to achieve adequate control with 
OADs in China.
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Objectives: Long-term safety trials for new antidiabetic therapies are beginning 
to provide an alternative data source to inform the burden of patients with high 
cardiovascular (CV) risk who are of concern to payers, but are often excluded from 
efficacy trials. An economic model was used to anticipate the availability of CV 
safety outcome data from ongoing trials and assess the clinical, economic and 
quality of life impacts in patients with different high risk profiles. MethOds: A 
discrete event simulation model was developed to capture 6 types of macrovas-
cular events and 2 key treatment events among patients with diabetes at high 
CV risk due to coronary heart disease (CHD), stroke and/or peripheral artery dis-
ease (PAD). Risk of clinical events depended on demographics and event history 
per UKPDS equations. Costs and utility values were based on published literature. 
Model outputs included event rates, CV-related costs and quality-adjusted life-years 
(QALYs). Results: Over a lifetime, in an example population with mean age of 
60 years, mean HbA1C of 8.5%, 70% CHD history, 30% stroke history and 30% PAD 
history, the CV event rate was 25.1/100-patient-years and annual per-patient cost 
was $12,776. This translated into 10.5 QALYs overall, ranging from 9.3 (patients with 
stroke history) to 11.2 (patients with CHD only) QALYs. A new intervention that 
reduces all CV event risks by 20%, results in 12.2 QALYs and annual cost of $10,611 
for the overall population. These burdens vary by up to 14% for plausible values of 
event risk after multiple events, with the burden among patients with stroke his-
tory being most sensitive. cOnclusiOns: The clinical burden of CV events and the 
associated cost of care for patients with diabetes vary with baseline patient history 
and are subject to significant uncertainty. CV safety trials may provide clinical data 
to better quantify those burdens.
and needle. Results: 1) 614 patients with T2DM were surveyed and 71.45% used 
SMBG. For SMBG users, annual costs of glucometers were CNY 212.99; annual costs 
of test strips were CNY 825.55, estimated by multiplying average price (CNY 4.41) and 
frequency (3.60 per week); in total, SMBG cost CNY 1038.54 per person per year; 2) 
For insulin users, annual cost of insulin pens were CNY 396.34, estimated by average 
price (CNY 281.09) and frequency (1.41 per year); annual costs of needles were CNY 
634.20, estimated by average price (CNY 3.1) and frequency (204.58 per year, average 
reuse= 17.05 times); in total, self-injection cost CNY 1030.54 per person per year; 3) 
49.35% of surveyed patients used both insulin and SMBG. For this subgroup, annual 
costs of glucometers were CNY 199.05; annual costs of test strips were CNY 941.99, 
estimated by average price (CNY 4.41) and frequency (4.08 per week); In total was 
CNY 1141.04 per person per year. cOnclusiOns: SMBG and self-injection caused 
considerable economic burdens to patients with T2DM in major cities in China, and 
more attention should be given to their out-of-pocket payment incurred by self-used 
devices and supplies.
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Objectives: To investigate the frequency and cost of insulin pen needles reuse, 
and explore the factors that associated with needles reuse for insulin-treated dia-
betes patients in China. MethOds: A questionnaire-based survey was conducted 
in 7 medical centres across China from June to September of 2012. Type 1 and type 
2 diabetes patients treated with insulin were included in the study. The data were 
analysed by descriptive analysis, Spearman correlation analysis, K-W and M-W 
U test using SPSS 19.0. Results: 592 eligible respondents (30 type 1 and 562 type 
2 diabetes patients) were included. One single needle was used 10.57 times base 
on 5% trimmed mean (8 times in median). 89.2% of patients reuse needles and 
60.5% reuse > 6 times. Among type 1 and type 2 diabetes, needles use frequencies 
base on 5% trimmed mean were 7.19 times (6 times in median) and 10.76 times 
(9 times in median), reuse of needles were 86.7% and 89.4%, needles reuse> 6 
times were 36.7% and 61.7%, respectively. Annual cost of needles was 237.0 CNY, 
estimated by the needle price of 2013 (NovoFine 32GTip, Novo Nordisk). The cost 
would be 2504.9 CNY/year if needles were used 1 time only. Economics burden was 
the most important factor of needles reuse for 68.9% of patients. Needles reuse 
was statistically and positively associated with age, diabetes duration, number of 
complications, value of fasting blood glucose, insulin injections times and dose, 
and was negative associated with income, with P-value< 0.05. cOnclusiOns: 
Needles reuse for insulin injection was a common phenomenon in insulin-treated 
diabetes patients in China. Economic burden was the main reason of needles 
reuse. Other influencing factors of needles reuse included age, diabetes-related 
health status and insulin use.
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Objectives: To describe the prevalence, frequency and cost of SMBG, and explore the 
factors that influence SMBG for insulin-treated diabetes patients in China. MethOds: 
A questionnaire-based survey was conducted in 7 medical centres across China from 
June to September of 2012. Type 1 and type 2 diabetes patients treated with insulin 
were included in the study. The data were analysed by descriptive analysis, Spearman 
correlation analysis, K-W and M-W U test using SPSS 19.0. Results: 602 eligible 
respondents (4.98% type 1 and 95.02% type 2 diabetes patients) were included. 85.0% 
of patients practiced SMBG with the frequency of 0.61±0.94 times/day. Among type 1 
and type 2 diabetes patients, the prevalence and frequency of SMBG were 90.0% and 
1.05 times/day, 84.8% and 0.59 times/day, respectively. Taking global recommended 
SMBG frequency into account, only 18.76% of type 2 diabetes patients conducted 
SMBG ≥ 1 time/day, and 7.4% of type 1 diabetes patients conducted SMBG ≥ 3 times/
day. Annual cost of SMBG was 1170 CNY, estimated by the market price of 5 CNY/
test trip. 20.5% of patients thought the cost of test trips was the most important 
factor to SMBG use. SMBG frequency was statistically and positively correlated with 
frequency and doses of insulin daily use, frequency and related cost of hypoglycae-
mia, drug cost, frequency and cost of hospitalization and clinical visit, with P-value 
< 0.05. cOnclusiOns: SMBG was not conducted enough in insulin-treated diabetes 
patients in China. Economic burden of test trips was one of the main barriers to 
SMBG use. Factors influencing SMBG included insulin use, hypoglycaemia, drug costs, 
frequency and cost of hospitalization and clinic visit.
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